[D] Indaptus Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Indaptus Therapeutics, Inc. (CIK 0001857044) filed a Form D notice with the SEC to report a new exempt offering of securities. The biotechnology company, incorporated in Delaware in 2021 and operating from 3 Columbus Circle, New York, is claiming the Rule 506(c) exemption, which allows general solicitation provided that all purchasers are accredited investors.

Offering details:

• Date of first sale: 12 June 2025
• Securities offered: (i) Options, warrants, or other rights to acquire another security and (ii) the underlying securities issuable upon exercise of those rights
• Minimum investment: $0 USD, indicating flexibility for investor entry size
• Offering duration: The issuer does not expect the offering to last more than one year
• Issuer size: The company elected “Decline to Disclose” for both revenue and asset ranges

Intermediary & solicitation: Paulson Investment Company, LLC (CRD 000005670) is identified as the broker-dealer. Solicitation will occur in multiple U.S. states (e.g., CA, CO, FL) and in foreign jurisdictions.

Management & directors: The filing lists key executives and directors, including CEO Jeffrey A. Meckler, CFO Nir Sassi, and several directors such as Roger J. Pomerantz and Hila Karah. No promoters are designated.

Other disclosures: • The offering is not tied to a business-combination transaction.
• No sales compensation recipients beyond Paulson Investment Company are disclosed.
• The issuer is categorised under the “Pharmaceuticals” industry segment.

Information gaps: Items concerning total amount offered, sold, and remaining are not present in the excerpt, limiting visibility into potential dilution and capital inflow.

Positive

• Access to capital: Filing enables Indaptus to solicit accredited investors broadly under Rule 506(c), potentially strengthening its cash position for clinical development.

Negative

• Potential dilution: Issuance of options/warrants and underlying securities could dilute existing shareholders once exercised.
• Lack of transparency: Offering size, proceeds usage and financial metrics are not disclosed, limiting investor visibility.

Insights

Securities Analyst

TL;DR – Private placement under Rule 506(c); size undisclosed, potential dilution, capital access.

Indaptus is leveraging Rule 506(c) to raise capital through warrants/options, suggesting a preference for accredited-investor funding without full public-market scrutiny. The absence of aggregate offering size data prevents valuation of dilution impact, yet the structure implies future equity issuance once instruments are exercised. Engagement of Paulson Investment Company indicates an established placement channel across multiple states and abroad. Investors should monitor subsequent amendments for dollar amounts and closing status.

Biotech Industry Specialist

TL;DR – Capital raise supports R&D runway; warrants align with risk-tolerant biotech financing.

Biotech firms like Indaptus often use warrant-based raises to fund clinical programs without immediate cash burn from exercised shares. A Rule 506(c) filing signals urgency for cash while maintaining control through accredited investor participation. However, lack of financial metrics curtails insight into whether this is opportunistic or necessity driven. Watch for subsequent disclosures on amount raised and program milestones.

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL

OMB Number:			3235-0076
Estimated average burden
hours per response:			4.00

1. Issuer's Identity

CIK (Filer ID Number)

Previous Names

None

Entity Type

0001857044

Intec Parent Inc.

X	Corporation
	Limited Partnership
	Limited Liability Company
	General Partnership
	Business Trust
	Other (Specify)

Name of Issuer

Indaptus Therapeutics, Inc.

Jurisdiction of Incorporation/Organization

DELAWARE

Year of Incorporation/Organization

	Over Five Years Ago
X	Within Last Five Years (Specify Year)	2021
	Yet to Be Formed

2. Principal Place of Business and Contact Information

Name of Issuer
Indaptus Therapeutics, Inc.
Street Address 1		Street Address 2
3 COLUMBUS CIRCLE
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
NEW YORK	NEW YORK	10019	(646) 427-2727

3. Related Persons

Last Name	First Name	Middle Name
Meckler	Jeffrey	A.
Street Address 1	Street Address 2
Indaptus Therapeutics, Inc.	3 Columbus Circle, 15th Floor
City	State/Province/Country	ZIP/PostalCode
New York	NEW YORK	10019

Relationship: X Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Newman	Michael	J
Street Address 1	Street Address 2
Indaptus Therapeutics, Inc.	3 Columbus Circle, 15th Floor
City	State/Province/Country	ZIP/PostalCode
New York	NEW YORK	10019

Relationship: X Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Sassi	Nir
Street Address 1	Street Address 2
Indaptus Therapeutics, Inc.	3 Columbus Circle, 15th Floor
City	State/Province/Country	ZIP/PostalCode
New York	NEW YORK	10019

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Linscott	Walt	A.
Street Address 1	Street Address 2
Indaptus Therapeutics, Inc.	3 Columbus Circle, 15th Floor
City	State/Province/Country	ZIP/PostalCode
New York	NEW YORK	10019

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Waltzman	Roger	J.
Street Address 1	Street Address 2
Indaptus Therapeutics, Inc.	3 Columbus Circle, 15th Floor
City	State/Province/Country	ZIP/PostalCode
New York	NEW YORK	10019

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Pomerantz	Roger	J.
Street Address 1	Street Address 2
Indaptus Therapeutics, Inc.	3 Columbus Circle, 15th Floor
City	State/Province/Country	ZIP/PostalCode
New York	NEW YORK	10019

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Karah	Hila
Street Address 1	Street Address 2
Indaptus Therapeutics, Inc.	3 Columbus Circle, 15th Floor
City	State/Province/Country	ZIP/PostalCode
New York	NEW YORK	10019

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Maddaluna	Anthony	J.
Street Address 1	Street Address 2
Indaptus Therapeutics, Inc.	3 Columbus Circle, 15th Floor
City	State/Province/Country	ZIP/PostalCode
New York	NEW YORK	10019

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Hayes	William	B.
Street Address 1	Street Address 2
Indaptus Therapeutics, Inc.	3 Columbus Circle, 15th Floor
City	State/Province/Country	ZIP/PostalCode
New York	NEW YORK	10019

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Gilbert	Mark	J.
Street Address 1	Street Address 2
Indaptus Therapeutics, Inc.	3 Columbus Circle, 15th Floor
City	State/Province/Country	ZIP/PostalCode
New York	NEW YORK	10019

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Martell	Robert	E.
Street Address 1	Street Address 2
Indaptus Therapeutics, Inc.	3 Columbus Circle, 15th Floor
City	State/Province/Country	ZIP/PostalCode
New York	NEW YORK	10019

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

4. Industry Group

Agriculture

Banking & Financial Services

Commercial Banking

Insurance

Investing

Investment Banking

Pooled Investment Fund

Is the issuer registered as
an investment company under
the Investment Company
Act of 1940?

Yes No

Other Banking & Financial Services

Business Services

Energy

Coal Mining

Electric Utilities

Energy Conservation

Environmental Services

Oil & Gas

Other Energy

	Health Care
	Biotechnology
	Health Insurance
	Hospitals & Physicians
	X Pharmaceuticals
	Other Health Care
	Manufacturing
	Real Estate
	Commercial
	Construction
	REITS & Finance
	Residential
	Other Real Estate

Retailing

Restaurants

Technology

Computers

Telecommunications

Other Technology

Travel

Airlines & Airports

Lodging & Conventions

Tourism & Travel Services

Other Travel

Other

5. Issuer Size

Revenue Range		OR	Aggregate Net Asset Value Range
	No Revenues			No Aggregate Net Asset Value
	$1 - $1,000,000			$1 - $5,000,000
	$1,000,001 - $5,000,000			$5,000,001 - $25,000,000
	$5,000,001 - $25,000,000			$25,000,001 - $50,000,000
	$25,000,001 - $100,000,000			$50,000,001 - $100,000,000
	Over $100,000,000			Over $100,000,000
X	Decline to Disclose			Decline to Disclose
	Not Applicable			Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

		Rule 504(b)(1) (not (i), (ii) or (iii))
		Rule 504 (b)(1)(i)
		Rule 504 (b)(1)(ii)
		Rule 504 (b)(1)(iii)
		Rule 506(b)
	X	Rule 506(c)
		Securities Act Section 4(a)(5)

Investment Company Act Section 3(c)

Section 3(c)(1) Section 3(c)(9)

Section 3(c)(2) Section 3(c)(10)

Section 3(c)(3) Section 3(c)(11)

Section 3(c)(4) Section 3(c)(12)

Section 3(c)(5) Section 3(c)(13)

Section 3(c)(6) Section 3(c)(14)

Section 3(c)(7)

7. Type of Filing

X	New Notice			Date of First Sale	2025-06-12				First Sale Yet to Occur
	Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year? Yes X No

9. Type(s) of Securities Offered (select all that apply)

	Equity		Pooled Investment Fund Interests
	Debt		Tenant-in-Common Securities
X	Option, Warrant or Other Right to Acquire Another Security		Mineral Property Securities
X	Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security		Other (describe)

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? Yes X No

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor $0 USD

12. Sales Compensation

Recipient	Recipient CRD Number None
Paulson Investment Company, LLC	000005670
(Associated) Broker or Dealer X None	(Associated) Broker or Dealer CRD Number X None
None	None
Street Address 1	Street Address 2
10220 SW Greenburg Rd	Suite 380
City	State/Province/Country	ZIP/Postal Code
Portland	OREGON	97223
State(s) of Solicitation (select all that apply) Check "All States" or check individual States All States	X Foreign/non-US
CALIFORNIA COLORADO FLORIDA GEORGIA HAWAII IDAHO ILLINOIS KANSAS MARYLAND MASSACHUSETTS MICHIGAN MINNESOTA NEVADA NEW JERSEY NEW YORK NORTH CAROLINA OKLAHOMA OREGON PENNSYLVANIA SOUTH CAROLINA TEXAS UTAH VIRGINIA WASHINGTON WISCONSIN

13. Offering and Sales Amounts

Total Offering Amount	$5,000,000	USD	or Indefinite
Total Amount Sold	$2,314,800	USD
Total Remaining to be Sold	$2,685,200	USD	or Indefinite

Clarification of Response (if Necessary):

Offering of convertible notes in the aggregate principal amount of up to $5 million, convertible into shares of common stock, together with warrants to purchase shares of common stock. Approximately $2.3 million raised as of initial closing date.

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

20

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions	$600,000	USD	X Estimate
Finders' Fees	$0	USD	Estimate

Clarification of Response (if Necessary):

The Issuer paid the placement agent (i) 12% of gross proceeds in the offering, (ii) a $25,000 non-accountable expense and (iii) a number of warrants equal to 12% of the shares issuable upon conversion of the notes sold in the offering.

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

$0

USD

Estimate

Clarification of Response (if Necessary):

The Company intends to use the net proceeds from the Offering for research and development activities including the funding of a Phase 1b/2 clinical trial as well as for working capital and general corporate purposes.

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

• Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*

• Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.

• Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Indaptus Therapeutics, Inc.	/s/ Nir Sassi	Nir Sassi	Chief Financial Officer	2025-06-20

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.

FAQ

What exemption is Indaptus Therapeutics (INDP) using for its private placement?

The company is claiming the Rule 506(c) exemption under Regulation D, allowing general solicitation to accredited investors.

When did the Form D indicate the first sale occurred?

The notice states the first sale date as 12 June 2025.

What type of securities is Indaptus offering?

Indaptus is offering warrants/options and the underlying securities issuable upon exercise of those instruments.

Is there a minimum investment amount for outside investors?

No. The filing lists a $0 minimum investment, implying flexible participation thresholds.

Which broker-dealer is involved in the offering?

Paulson Investment Company, LLC (CRD 000005670) is the associated broker-dealer.

Does the company disclose revenues or asset size in the filing?

No. Indaptus selected “Decline to Disclose” for both revenue and aggregate net asset value ranges.